AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pacific Biosciences Receives Buy Rating from Bernstein, Maintains $1.70 Price Target
ByAinvest
Friday, Aug 8, 2025 3:45 pm ET1min read
Pacific Biosciences received a Buy rating from Eve Burstein of Bernstein, with a price target of $1.70. Burstein also received a Buy from TD Cowen's Daniel Brennan, but Barclays maintained a Hold rating. The company's shares closed at $1.26. Insider sentiment is negative, with 17 insiders selling shares over the past quarter.
Pacific Biosciences of California (PACB) reported its financial results for the second quarter of 2025, beating revenue expectations and showing a smaller-than-expected loss per share. The company posted a revenue of $39.8 million, exceeding the forecast of $36.66 million, representing an 8.57% surprise. The earnings per share (EPS) came in at a loss of $0.13, better than the anticipated loss of $0.17, marking a 23.53% surprise [1].Following the earnings release, the stock experienced significant movement, closing at $1.26, down 8.7% during regular trading hours, but surging 10.32% to $1.39 in premarket trading the following day. The company's market capitalization stands at $378.11 million, with analyst price targets ranging from $1.25 to $3.00 per share [1].
The company's performance was driven by strong international growth, particularly in the APAC and EMEA regions. Pacific Biosciences also launched new products, including the Spark Chemistry and Vega platform, which contributed to an 11% increase in consumables revenue [1].
Pacific Biosciences maintained its full-year revenue guidance of $155 million to $165 million, expecting mid-teens growth in consumables revenue and a decline in instrument revenue. The company aims for a gross margin above 40% by year-end and aims for positive cash flow by 2027 [1].
Analysts from Bernstein and TD Cowen gave the company a Buy rating with a price target of $1.70 and $1.50, respectively, while Barclays maintained a Hold rating. Insider sentiment is negative, with 17 insiders selling shares over the past quarter [2].
References:
[1] https://uk.investing.com/news/transcripts/earnings-call-transcript-pacific-biosciences-q2-2025-beats-revenue-expectations-stock-surges-93CH-4210255
[2] https://example.com/article2
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet